OCG programs support research on structural, functional, and translational genomics, as well as the development of next-generation cancer models. These programs promote advances in technology and provide accessibility to data, tools, and reagents for the research community worldwide. OCG programs interconnect with other genomics and translational projects in order to accelerate discoveries into the clinic and improve patient outcomes.
Below are OCG’s current and completed programs:
The Cancer Genome Characterization Initiative (CGCI) uses molecular characterization to uncover distinct features of rare cancers. Current projects perform comprehensive molecular cataloging of HIV+ and other rare adult and pediatric cancers. The research community can use CGCI data to gain insights into the underlying mechanisms of these cancers and identify potential therapeutic targets.
The Cancer Target Discovery and Development (CTD²) Network, a functional genomics initiative, bridges the gap between genomics and development of effective therapeutics. The Network aims to understand tumor development, heterogeneity, drug resistance, and metastasis to develop optimal combinations of chemotherapy with immunotherapy.
The Human Cancer Models Initiative (HCMI) is an international consortium that is generating novel, next-generation, tumor-derived culture models annotated with genomic, clinical, and biospecimen data. HCMI-developed models and case-associated data are available as a community resource. NCI is contributing to the initiative by supporting four Cancer Model Development Centers (CMDCs).
Next-Generation Technologies (NGT) Program supports the development of technology tools that will facilitate and/or accelerate research using advanced human-derived next-generation cancer models such as organoids, conditionally reprogrammed cells, and others. The tools will focus on utilizing next-generation cancer models from the Human Cancer Models Initiative.
The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) program applies a comprehensive genomic approach to determine molecular changes that drive childhood cancers. The goal of the program is to use data to guide the development of effective, less toxic therapies. TARGET is organized into a collaborative network of disease-specific project teams.
CGAP: Cancer Genome Anatomy Project
The Cancer Genome Anatomy Project (CGAP) data no longer exist. The Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer has a new home at the Institute for Systems Biology Cancer Genomics Cloud. The Mitelman Database relates chromosomal aberrations to tumor characteristics, based either on individual cases or associations.
ICG: Initiative for Chemical Genetics
The Initiative for Chemical Genetics (ICG) provides a systematic approach to studying biology through small molecule probes and screens so that new therapies for diseases like cancer can be developed.